A Public Application
Kim Han-sol, known online as OneshotHansol, has announced his application to participate in Neuralink’s clinical trial for Blindsight, the company’s experimental vision-restoring brain-computer interface. Kim, who has 1.68 million YouTube subscribers, uploaded a video on February 7 announcing his decision. The video went viral approximately three weeks later, drawing widespread attention to the trial.
Blindsight combines a brain implant with camera-mounted glasses. The system is designed to enable visually impaired individuals to perceive their surroundings through the implanted chip, initially providing low-resolution vision with the potential for higher resolution over time. Neuralink says the device is intended to help even those with complete vision loss.
Public Reaction and Clinical Reality
Viewer responses have been divided. Supporters expressed hope that the trial could restore Kim’s sight, while others raised concerns about the risks inherent in experimental brain surgery. That tension — between the promise of neural interfaces and the uncertainties of early-stage implantation — is one the BCI industry will face repeatedly as clinical trials expand and public figures volunteer as participants.
Neuralink, founded in 2016 by Elon Musk and eight scientists and engineers, has been conducting human trials of its brain-computer interface technology. The Blindsight program represents the company’s push beyond motor-function applications into sensory restoration, a technically distinct challenge that requires the implant to deliver information to the brain rather than merely read signals from it.
Why It Matters
High-profile volunteers change the public calculus around BCI trials. When a creator with more than a million followers documents the decision to undergo experimental brain surgery, the audience engagement dwarfs anything a clinical recruitment campaign could achieve. For Neuralink, this is both an opportunity and a liability — heightened visibility accelerates awareness but also amplifies scrutiny of outcomes.